CureVac and GSK to receive money and royalties from BioNTech/Pfizer as part of mRNA patent settlement

BioNTech settled a three-year mRNA patent dispute with GSK and CureVac, a fellow German biotech that it's in the process of acquiring. BioNTech gained fame during the Covid-19 pandemic through its work developing a vaccine ...